Quanterix Corporation (NASDAQ: QTRX) announced on November 18, 2026, that Everett Cunningham has resigned as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. The resignation is not related to any disagreements regarding the company's operations, policies, or financial disclosures.

Mr. Cunningham will remain available to assist with an orderly transition of his responsibilities through December 11, 2026. In his place, the Board has appointed James Gute, the company's current Chief Commercial Officer, to serve as Interim President and Chief Executive Officer.

Mr. Gute, age 52, joined Quanterix in August 2026 as Chief Commercial Officer. Prior to joining the company, he served as Senior Vice President and Commercial Manager, General Screening at Exact Sciences (now Abbott Laboratories, Cancer Diagnostics) from August 2024 to August 2026, and as General Manager, Western Region at the same organization from January 2022 to August 2024. Before that, he spent 18 years at GE Healthcare, most recently serving as President of the North Central Region.

The Board has engaged a nationally recognized executive search firm to assist with the process of finding a permanent CEO and will consider both internal and external candidates. In connection with his appointment as Interim CEO, Mr. Gute will be paid an annualized salary of $750,000.

Quanterix reaffirmed its 2026 business outlook as provided on November 9, 2026.